書籍詳細

1 治療を始める前に

P.32 掲載の参考文献

• ●Dunitz M. Myeloma (Mehta J, Singhai S, eds). Taylor and Francis Group, 2002:1-901865-50-9.

• ●Bataille R, Harousseau JL. Multiple myeloma. New England Journal of Medicine. 1997; 336:1657-1664.
  pubmed

• ●Kyle RA. History of multiple myeloma. In:Neoplastic Diseases of the Blood, 3rd edition. (Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds). New York:Churchill Livingstone, 1996.

• ●Kyle RA. History of multiple myeloma. In:Neoplastic Diseases of the Blood, 2nd edition. (Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds). New York:Churchill Livingstone, 1991:325-32.

• ●Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52:23-47.

• ●Schwartz GG. Multiple myeloma:clusters, clues, and dioxins. Cancer Epidemiol Biomarkers Prev. 1997; 6:49-56.
  pubmed

• ●Schottenfeld D, Fraumeni JF Jr. (eds). Cancer Epidemiology and Prevention, 2nd edn. New York:Oxford University Press; 1996:946-970.

• ●Herrington LJ, Weiss NS, Olshan AF. The epidemiology of myeloma. In:Myeloma Biology and Management (Malpas JS, Bergsagel DE, Kyle RA eds.) Oxford, England, Oxford University Press:1995:127-168.

• ●Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolyticc lesions of multiple myeloma:a phase III, double blind, comparative trial. Cancer J. 2001; 7:377-387.
  pubmed

• ●Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomised, controlled clinical trials. Journal of Clinical Oncology. 2001; 19, 558-67.

• ●Berenson J, et al. Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. Journal of Clinical Oncology. 1998; 16:593-602.
  pubmed

• ●McCloskey EV, et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology. 1998; 100:317-25.
  pubmed

• ●Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. New England Journal of Medicine. 1998; 339:398-400.
  pubmed

• ●Berenson J, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine. 1996; 334:488-493.
  pubmed

• ●Bataille R, et al. Mechanism of bone destruction in multiple myeloma. The importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology. 1989; 7:1909.
  pubmed

• ●Durie BGM, Salmon SE, Mundy GR. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. British Journal of Haematology. 1981; 47:21-26.

• ●Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patiens with multiple myeloma. Journal of Clinical Oncology. 2000; 18:804-812.

• ●Durie BGM, et al. Cytogenetic abnormalities in multiple myeloma. Epidemiology and Biology of Multiple Myeloma. New York:Springer-Verlag, 1991:137-41.

• ●Kyle RA, Therneau TM, Rajkumar SV, Offord JR. A long-term study of prognosis in monoclanal gammopathy of undertermined significance. New England Journal of Medicine. 2002; 346:564-569.

• ●Weber DM, et al. Prognostic features of asymptomatic multipe myeloma. British Journal of Haematology. 1997; 97:810-4.

• ●Kyle RA, Greipp PR. Smoldering multiple myeloma. New England Journal of Medicine. 1980; 302:1347-49.
  pubmed

• ●Facon T, et al. Chromosome 13 abnormalities identified by FISH analysis and serum ?2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-71.
  pubmed

• ●Zojer N, et al. Deletion of 13q14 remains an independent prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hydridisation. Blood 2001; 95:1925-30.

• ●Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and ?2-microglobulin produce a simple and powerful myeloma staging system. Blood. 1992; 80:733-7.

• ●Durie BGM, Stock-Novack D, Salmon SE, et al. Prognostic value of pre-treatment serum B2 micro-globulin in myeloma:a Southwest Oncology Group study. Blood. 1990; 75:823-30.

• ●Greipp PR, et al. Value of ?2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988; 72:219-23.
  pubmed

• ●Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975; 36:842-54.

• ●Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology. 1998; 16:3832-42.

• ●Alexanian R, et al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992; 80:887-90.
  pubmed

• ●MacLennan ICM, et al, for the MRC Working Party on Leukaemia in Adults. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet. 1992; 339:200-5.

• ●Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for myeloma. American Journal of Hematology. 1990; 33:86-9.
  pubmed

• ●Alexanian R, et al. Treatment for multiple myeloma:combination chemotherapy with different melphalan dose regimes. Journal of the American Medical Association. 1969; 208:1680-5.

• ●Alexanian R. Dimopulus M. The treatment of multiple myeloma. New England Journal of Medicine 1994;330:484-9.

• ●Buzaid AC, Durie BGM. Management of refractory myeloma? a review. Journal of Clinical Oncology 1988; 6:889-905.

• ●Blade J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma:benefit for a small proportion of patients? Med Oncology. 2000; 77-84.
  pubmed

• ●Mandelli F, et al. Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. Results of an Italian randomized study. New England Journal of Medicine. 1990; 322:1430.

• ●Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine 1990; 322:1693-9.
  pubmed

• ●Musto P, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma:role of cytokines and monitoring of erythropoiesis. European Journal of Haematoloy. 1997; 58:314-19.

• ●Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of Clinical Oncology. 2000; 18:2273-81.

• ●Desikau KR, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1000 patients with multiple myeloma:durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000; 95:4008-4010.

• ●Barlogie B, Jagannath S, Desikau KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999; 93:55-65.

• ●Cunningham D, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma:long-term follow-up results. British Journal of Haematology. 1998; 102:495-502.

• ●Mehta J, Powles RL. Autologous blood and marrow transplantation. In:Leukaemia and Associated Diseases. (Whittaker JA, Holmes JA, eds). Oxford:Blackwell Science, 1998; 455-81.

• ●Fermaud JP, Ravaud P, Chevert S, et al. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma:upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998; 92:3131-3136.
  pubmed

• ●Attal M, Harousseau JL, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotheraphy in multiple myeloma. New England Journal of Medicine. 1996; 335:91-97.

• ●Gore ME, Viner C, Meldrum M. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet. 1989; 14:879.

• ●McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983; 2:822.
  pubmed

• ●Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogeneic graft-vs-myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood. 2001; 98 (11, pt 1):435a Abstract 2063.

• ●Gahrton G, et al. Progress in allogeneic hematopoietic stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2000; 25 (suppl. 1):S54.

• ●Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma:an analysis of risk factors on outcome. Blood. 1996; 88:2787-2793.
  pubmed

• ●Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant. 1996; 18:527-31.
  pubmed

• ●Durie BGM, Gale RP, Horowitz MM. Allogeneic and twin transplants for multiple myeloma:an IBMTR analysis. Multiple myeloma. From biology to therapy. Current concepts. INSERM, Mulhouse, 24-26 October, 1994 (abstract).

• ●Samson, D. The current position of allogeneic and autologous BMT in multiple myeloma. Leukemia and Lymphoma. 1992; 7:33.
  pubmed

• ●Gahrton G, Tura S, Ljungman P, et al. Allogenic bone marrow transplantation in multiple myeloma. New England Journal of Medicine. 1991; 325:1267.
  pubmed

• ●Oken M, Pomeroy C, Weisdorf D, et al. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. American Journal of Medicine. 1996; 100:624-28.
  pubmed

• ●Kyle RA, Gertz MA. Primary systemic amyloidosis:clinial and laboratory features in 474 cases. Semin Hematology. 1995; 32:45-59.

• ●Chapel HM, Lee M, Hargreaves R, et al. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lance. 1994; 343:1059-1063.

• ●Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch Internal Medicine. 1990; 150:863-69.

• ●Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients with relapsed/refractory disease. Proc Am Soc Clin Oncol. 2002; 21:11a.

• ●Richardson P, Schlossman RL, Hideshima F, et al. A phase I study of oral CC5013, an immunomodulatory Thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma. Blood. 2001; 98:775a.

• ●Hussein MA, Mason J, Ravandi F, Rifkin R. A phase II clinical study of arsenic tioxide (ATO) in patients with relapsed or refractory multiple myeloma; a preliminary report. Blood. 2001; 98:378a.

• ●Thomas D, Cortes J, O' Brien SM, et al. R115777, a farnesyl transferace inhibitor (FTI), has significant anti-leukaemia activity in patients with chronic myeloid leukaemia (CML). Blood. 2001; 98:727a.

• ●Barlogie B, Desikau KR, Eddelman P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients. Blood. 1995; 32:45-59.